Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2009; Volume 195, Supplement 667
XXXV Congress of The Spanish Society for Physiological Sciences
2/17/2009-2/20/2009
Valencia, Spain


MELATONIN PREVENTS ANDROGEN RECEPTOR ACTIVATION IN PROSTATE CANCER CELLS BY A REDOX MECHANISM
Abstract number: P149

Mayo1 JC, Quiros1 I, Hevia1 D, Garcia-Suarez1 O, Sainz1 RM

1Instituto Universitario Oncolgico del Principado de Asturias (IUOPA), Departamento de Morfologa y Biologa Celular, Facultad de Medicina, Oviedo. [email protected]

Aim: 

Prostate cancer is one of the most common aging-related diseases in western countries, while its prevalence in Asian countries with diets rich in antioxidants is much less frequent. Therefore many studies have been focused in the use of some antioxidants as chemopreventive agents. We have shown that the antioxidant pineal indole melatonin halts cell proliferation and induces neuroendocrine like differentiation in human epithelial prostate cancer cells The goal of the present study was to compare the actions of melatonin as a potential neuroendocrine--like differentiating agent with androgen withdrawal-induced NE differentiation, regarding the main role of androgen receptor.

Methods: 

We used confocal microscopy and protein levels of neuroendocrine markers to compare the phenotype of androgen-deprived or melatonin treated androgen dependent prostate cancer cells. Additionally we employed a whole genome microarray to compare the gene expression profiling between melatonin treated and androgen-deprived prostate cancer cells, in order to study potential gene expression pathways involved in androgen regulation. Finally, androgen receptor nuclear translocation was localized and quantified by using confocal microscopy and western blotting.

Results: 

Both, melatonin and androgen deprivation induces neuroendocrine-like differentiation with similar morphological and biochemical patterns. Genome microarray assay shows that both melatonin and androgen deprivation shares a common gene expression profiling. Androgen metabolism-related genes are not altered in melatonin treated cells, although some androgen-regulated genes (i.e. kallikrein) are profoundly downregulated in both groups. More interestingly, melatonin is able to prevent androgen receptor activation, keeping it in the cytosol after testosterone stimulation.

Conclusion: 

Melatonin, also at pharmacological concentrations, shows anti-androgenic properties in prostate cancer cells by sequestering AR in the cytoplam, without changing any androgen-metabolism-related genes.

To cite this abstract, please use the following information:
Acta Physiologica 2009; Volume 195, Supplement 667 :P149

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE